Roivant Sciences Ltd (NAS:ROIVW)
$ 2.75 -0.11 (-3.85%) Market Cap: - Enterprise Value: - PE Ratio: 2.09 PB Ratio: 1.58 GF Score: 60/100

Roivant Sciences Ltd at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 10:15PM GMT
Lut Ming Cheng
JPMorgan Chase & Co, Research Division - Research Analyst

Good afternoon. Thanks for joining us for another session at the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. I'm joined by my associate Sean Kim, who is in the audience today.

On stage, we have Roivant's CEO, Matt Gline. I'll pass the mic to Matt shortly for a presentation followed by a live audience Q&A. If you're joining us live here in the audience today, you can submit the questions for the team through our conference portal or you can hold your hands up during the Q&A session. I'll pass this to Matt. Matt, the stage is yours.

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

Thank you. Good afternoon. Thanks for coming today. It's good to see some familiar faces, some new ones. It's a pleasure to be here. So I'm going to go through just a brief presentation. And then as Brian said, we'll hang out and answer some questions (inaudible). So I'm going to be making some forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot